Literature DB >> 15308510

A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.

E Hachulla1, J G Coghlan.   

Abstract

Evidence suggests that endothelin may have a fundamental role in scleroderma pathogenesis, including pulmonary arterial hypertension (PAH)--a leading cause of death in patients with scleroderma. Development of a new class of drug, endothelin receptor antagonists, heralds an improved outlook for patients with scleroderma and related diseases. Heightened vigilance towards early detection of PAH in scleroderma and a multidisciplinary approach to diagnosis and treatment may improve clinical outcomes for these patients.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15308510      PMCID： PMC1755145          DOI： 10.1136/ard.2003.017673

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  50 in total

Review 1.  Primary pulmonary hypertension.

Authors:  S Rich
Journal:  Prog Cardiovasc Dis       Date:  1988 Nov-Dec       Impact factor: 8.194

2.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

3.  Mortality in systemic sclerosis (scleroderma).

Authors:  P Lee; P Langevitz; C A Alderdice; M Aubrey; P A Baer; M Baron; D Buskila; J P Dutz; I Khostanteen; S Piper
Journal:  Q J Med       Date:  1992-02

4.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

5.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; M Yanagisawa; D Langleben; R P Michel; R Levy; H Shennib; S Kimura; T Masaki; W P Duguid; D J Stewart
Journal:  N Engl J Med       Date:  1993-06-17       Impact factor: 91.245

6.  Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats.

Authors:  S J Chen; Y F Chen; Q C Meng; J Durand; V S Dicarlo; S Oparil
Journal:  J Appl Physiol (1985)       Date:  1995-12

7.  Significance of plasma endothelin-1 levels in patients with systemic sclerosis.

Authors:  K Yamane; T Miyauchi; N Suzuki; T Yuhara; T Akama; H Suzuki; H Kashiwagi
Journal:  J Rheumatol       Date:  1992-10       Impact factor: 4.666

8.  Mortality in systemic sclerosis: a comparison with the general population.

Authors:  M Abu-Shakra; P Lee
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

Review 9.  Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis.

Authors:  K Yamane
Journal:  Intern Med       Date:  1994-10       Impact factor: 1.271

10.  Localization of endothelin-1 and its binding sites in scleroderma skin.

Authors:  R Vancheeswaran; A Azam; C Black; M R Dashwood
Journal:  J Rheumatol       Date:  1994-07       Impact factor: 4.666
View more
  12 in total

1.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Authors:  C P Denton; M Humbert; L Rubin; C M Black
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

2.  Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy.

Authors:  Shin-ya Kawashiri; Yukitaka Ueki; Kaoru Terada; Satoshi Yamasaki; Kiyoshi Aoyagi; Atsushi Kawakami
Journal:  Rheumatol Int       Date:  2013-09-27       Impact factor: 2.631

Review 3.  Systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Jérôme Le Pavec; Marc Humbert; Luc Mouthon; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2010-03-01       Impact factor: 21.405

4.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.

Authors:  U A Walker; A Tyndall; L Czirják; C Denton; D Farge-Bancel; O Kowal-Bielecka; U Müller-Ladner; C Bocelli-Tyndall; M Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2007-01-18       Impact factor: 19.103

5.  Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  Reda E Girgis; Adaani E Frost; Nicholas S Hill; Evelyn M Horn; David Langleben; Vallerie V McLaughlin; Ronald J Oudiz; Ivan M Robbins; James R Seibold; Shelley Shapiro; Victor F Tapson; Robyn J Barst
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

Review 6.  Genetics of systemic sclerosis-associated pulmonary arterial hypertension: recent progress and current concepts.

Authors:  Sanjiv J Shah
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

7.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

8.  Evidence for the involvement of type I interferon in pulmonary arterial hypertension.

Authors:  Peter M George; Eduardo Oliver; Peter Dorfmuller; Olivier D Dubois; Daniel M Reed; Nicholas S Kirkby; Nura A Mohamed; Frederic Perros; Fabrice Antigny; Elie Fadel; Benjamin E Schreiber; Alan M Holmes; Mark Southwood; Guy Hagan; Stephen J Wort; Nathan Bartlett; Nicholas W Morrell; John G Coghlan; Marc Humbert; Lan Zhao; Jane A Mitchell
Journal:  Circ Res       Date:  2013-12-13       Impact factor: 17.367

9.  Integrated care and optimal management of pulmonary arterial hypertension.

Authors:  Geoff Strange; Robin Fowler; Corina Jary; Brad Dalton; Simon Stewart; Eli Gabbay
Journal:  J Multidiscip Healthc       Date:  2009-05-12

10.  Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial.

Authors:  Marco Matucci-Cerinic; Christopher P Denton; Daniel E Furst; Maureen D Mayes; Vivien M Hsu; Patrick Carpentier; Fredrick M Wigley; Carol M Black; Barri J Fessler; Peter A Merkel; Janet E Pope; Nadera J Sweiss; Mittie K Doyle; Bernhard Hellmich; Thomas A Medsger; Adele Morganti; Fabrice Kramer; Joseph H Korn; James R Seibold
Journal:  Ann Rheum Dis       Date:  2010-08-30       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.